Trial site
Carl-Thiem-Klinikum Cottbus gGmbH
Cottbus, Brandenburg 03048, GermanyNot linked to an institution yet
- 15running trials
- 2closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Recruiting9 trials
- Active, not recruiting6 trials
- Completed2 trials
- Suspended1 trial
- Lead sponsor
- GPOH gGmbH2 trials
- Hoffmann-La Roche2 trials
- CENTOGENE GmbH Rostock1 trial
- Charite University, Berlin, Germany1 trial
- Incyte Corporation1 trial
- and 11 more
Running trials
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
NCT05384691· Phase 2· University of Leipzig· Source
Contact: Maximilian Desole, Dr.
Active, not recruiting
A phase II, open-label, single arm study to evaluate the efficacy of
Luspatercept in Erythropoiesis-stimulating agent naive lower-risk
MDS patients with or without ring sideroblasts who do not require
RBC transfusions
2024-516438-36-00· Phase 2· Universitaet Leipzig· Source
Recruiting
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
2022-501180-40-00· Phase 3· GPOH gGmbH· Source
Recruiting
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.
2024-510578-25-00· Phase 3· The University Of Birmingham· Source
Active, not recruiting
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
NCT04657289· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092· Phase 3· Incyte Corporation· Source
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494· Phase 3· University Hospital Muenster· Source
Active, not recruiting
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251· Phase 3· Hoffmann-La Roche· Source
Recruiting
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276· Phase 3· Martin Schrappe· Source
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· Phase 2· Charite University, Berlin, Germany· Source
Active, not recruiting
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
NCT02066220· Phase 2/3· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
NCT03188874· Technische Universität Dresden· Source
Contact: Martin Schmidt-Hieber, PD Dr.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error